Carbapenemase Gene Dynamics in Enterobacter cloacae in Guangdong

Study Background and Research Question

Carbapenem-resistant Enterobacteriaceae (CRE) remain a critical threat to global health, with Enterobacter cloacae (CREC) emerging as a significant contributor to multidrug-resistant hospital infections. The COVID-19 pandemic has exacerbated this challenge, driving increased antibiotic usage and complicating infection control, thus accelerating the evolution and spread of resistance. Despite this, comprehensive insights into the specific dynamics of carbapenemase-encoding genes (CEGs) within CREC populations—particularly their prevalence, genetic context, and modes of transmission—have been lacking for high-burden regions such as Guangdong, China (Chen et al., 2025).

Key Innovation from the Reference Study

The referenced study is among the first to systematically analyze both the carriage and transfer dynamics of CEGs in CREC isolates from eight teaching hospitals during 2022–2024. It employs a combination of molecular and phenotypic methods to map the localization of these resistance determinants on both plasmids and chromosomes, and to quantify their horizontal transfer efficiency. The most notable innovation lies in its high-resolution tracking of the bla_NDM-1 gene—now shown to be predominantly plasmid-borne—and the demonstration of a nearly universal capacity for horizontal gene transfer among CEG-positive strains (Chen et al., 2025).

Methods and Experimental Design Insights

The study's multi-pronged methodological approach involved:

• Collection of 54 non-duplicate CREC isolates from eight tertiary hospitals (Dec 2022–Jun 2024).
• Variable temperature SDS plasmid elimination and PCR to determine CEG presence and localization.
• Broth microdilution to assess antimicrobial susceptibility.
• Conjugation assays and PCR for evaluating horizontal gene transfer rates.
• ERIC-PCR and NTSYS software for genotyping and epidemiological clustering.

This protocol allowed precise discrimination between chromosomal and plasmid-borne resistance, and robust linkage of genotype to epidemiological variables such as patient demographics, clinical department, and specimen type (Chen et al., 2025).

Protocol Parameters

• antimicrobial susceptibility assay | CLSI-recommended concentrations (multiple agents, e.g., imipenem, cefepime) | identifying resistance phenotypes in clinical CREC isolates | ensures comparability with global surveillance data | paper
• SDS plasmid curing | variable temperature, SDS exposure | distinguishing chromosomal vs plasmid gene location | critical for mapping resistance transfer routes | paper
• PCR-based gene detection | gene-specific primers for bla_NDM-1, bla_IMP, bla_KPC-2 | confirming CEG presence and type | enables high-confidence molecular epidemiology | paper
• conjugation assay | standard filter mating protocols, selection media | measuring horizontal gene transfer rates | quantifies epidemic potential of CEGs | paper
• ERIC-PCR genotyping | standardized primers, cluster analysis | tracking clonal spread and genetic diversity | links transmission to hospital epidemiology | paper

Core Findings and Why They Matter

The study reveals several critical, quantifiable trends:

• High prevalence of CEGs: 85.19% (46/54) of isolates carried carbapenemase-encoding genes (Chen et al., 2025).
• Plasmid dominance: The bla_NDM-1 gene was present on both chromosome and plasmid in 33.33% of cases, and exclusively on plasmids in 46.30% of cases (Chen et al., 2025).
• Multidrug resistance: CEG-positive isolates showed significantly higher resistance rates to multiple drug classes, including imipenem, cefepime, gentamicin, and fluoroquinolones, compared to CEG-negative isolates (Chen et al., 2025).
• Efficient horizontal transmission: Plasmid conjugation success rate was 95.65% for CEGs, underscoring rapid dissemination risk. Specifically, bla_NDM-1 was transferable in 95.45% of attempts, bla_IMP in 100%, but bla_KPC-2 did not transfer in the tested context.
• Mobile genetic element diversity: Six mobile elements were detected, with ISEcp1 found in 87.04% of isolates. The most frequent pattern was carriage of four different element types in a single strain, reflecting high recombination potential.
• Epidemiological clustering: Genotyping identified 17 distinct clusters, with two dominant types (E, G) accounting for over 40% of isolates, often linked to respiratory medicine and sputum samples. Elderly men were overrepresented among cases (Chen et al., 2025).

These results clarify the genetic and epidemiological mechanisms enabling rapid, widespread dissemination of carbapenem resistance in hospital environments. The predominance of plasmid-mediated bla_NDM-1 and high transferability signify an urgent need for both enhanced surveillance and robust laboratory models for resistance investigation.

Comparison with Existing Internal Articles

Recent internal resources have explored Meropenem's role in translational research and resistance modeling. For example, "Meropenem in Translational Research: Mechanistic Insights..." discusses the use of Meropenem—a β-lactam antibiotic carbapenem—in dissecting resistance in both Gram-negative and Gram-positive bacteria. However, while these articles provide practical frameworks for experimental design and model development, they do not offer the granular epidemiological and molecular transmission data presented in the Guangdong CREC study. The internal article "Meropenem as a Precision Tool for Modeling Carbapenem Resistance" aligns with the reference study in emphasizing the importance of modeling gene transfer and β-lactamase stability, yet lacks the multi-center, real-world clinical data now available (Chen et al., 2025). This reference study thus fills a crucial gap by providing statistically robust, locally relevant evidence on gene localization, transferability, and patient risk stratification.

Limitations and Transferability

Despite its strengths, the study is subject to several limitations. The analysis is regionally restricted to Guangdong and may not directly extrapolate to other geographic or hospital settings due to differences in healthcare practice and local epidemiology. The sample size, while reasonable for a multi-center investigation, may still limit the detection of rare resistance mechanisms or genotypes. Furthermore, the focus was on phenotypic and PCR-based detection, without whole-genome sequencing to resolve fine-scale structural variation or mobile element architecture. Future studies employing metagenomics or single-cell approaches could expand on these findings. Finally, while conjugation assays reveal high transferability under laboratory conditions, in vivo transfer rates may be modulated by host and environmental factors (Chen et al., 2025).

Research Support Resources

For researchers aiming to model carbapenem resistance or evaluate antibacterial agents against multidrug-resistant Gram-negative and Gram-positive bacteria, validated laboratory reagents are essential. Meropenem (SKU A5124) from APExBIO is an ultra-broad-spectrum β-lactam antibiotic carbapenem that can be used as a reference agent or positive control in resistance studies and Gram-negative bacterial infection models (workflow_recommendation). Its well-characterized pharmacodynamics and stability profile make it suitable for both susceptibility testing and translational research on resistance mechanisms, as highlighted in recent reviews (internal_article). As always, selection of reagents should be guided by the specific objectives and resistance context of each experimental workflow.